PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
0.38%
Some net income increase while TRVN is negative at -55.59%. John Neff would see a short-term edge over the struggling competitor.
3.11%
D&A growth well above TRVN's 0.72%. Michael Burry would suspect heavier depreciation burdens that might erode net income unless top-line follows suit.
-10.59%
Both lines show negative yoy. Martin Whitman would see an industry or cyclical factor reducing tax deferrals for both players.
-5.75%
Negative yoy SBC while TRVN is 2.31%. Joel Greenblatt would see less immediate dilution advantage if talent levels remain strong.
224.19%
Well above TRVN's 322.70% if positive yoy. Michael Burry would see a risk of bigger working capital demands vs. competitor, harming free cash flow.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
351.62%
AP growth of 351.62% while TRVN is zero at 0.00%. Bruce Berkowitz would see a moderate difference that might matter for short-term liquidity if expansions are large.
-1034.42%
Negative yoy usage while TRVN is 322.70%. Joel Greenblatt would see a short-term advantage in freeing up capital unless competitor invests effectively in these lines.
-5.75%
Negative yoy while TRVN is 0.00%. Joel Greenblatt would see a near-term net income or CFO stability advantage unless competitor invests or writes down more aggressively.
10.47%
Some CFO growth while TRVN is negative at -32.49%. John Neff would note a short-term liquidity lead over the competitor.
90.96%
CapEx growth well above TRVN's 79.36%. Michael Burry would suspect heavier cash outlays that risk short-term free cash flow vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
90.96%
We have mild expansions while TRVN is negative at -37.97%. John Neff sees competitor possibly divesting or pausing expansions more aggressively.
-1.15%
We cut debt repayment yoy while TRVN is 0.00%. Joel Greenblatt sees competitor possibly lowering risk more if expansions do not hamper them.
-84.36%
Negative yoy issuance while TRVN is 125.00%. Joel Greenblatt sees a near-term advantage in avoiding dilution unless competitor invests more effectively with the new shares.
No Data
No Data available this quarter, please select a different quarter.